Molecular Diagnostics Market, By Product (Instruments, Reagents, and Other Products), By Technology (In Situ Hybridization, Chips and Microarrays, Mass Spectrometry (MS), Sequencing, PCR, and Other Technologies), By Application (Infectious Disease, Oncology, Pharmacogenomics, Microbiology, Genetic Disease Screening, Human Leukocyte Antigen Typing, and Blood Screening), By End User (Hospitals, Laboratories, and Other End Users), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Report Code: PMI9918 | Publish Date: March 2024 | No. of Pages: 145

Global Molecular Diagnostics Market By Overview

Molecular Diagnostics Market was valued at US$ 18.4 Billion in 2024 and is projected to grow at a CAGR of 11.50% to reach US$ 54.9 Billion by 2034.

Molecular Diagnostic tests are used for the detection of specific DNA or RNA sequences that may or may not be associated with diseases, including Single Nucleotide Polymorphism (SNP), and mutations (deletions, insertions, and rearrangements).

The rising prevalence of various infectious diseases and various types of cancer diseases is a major factor boosting the growth of the target market. The increasing adoption of unhealthy lifestyles by the population has led to the progression of several infectious diseases as well as cancer diseases, eventually leading to the growth of the Molecular Diagnostics Market.

For instance, in December 2022, according to an article published by the Indian Council of Medical Research, it was reported that cancer cases are speculated to increase from 14.6 lakh in the year 2022 to 15.7 lakh in the year 2025 in India.

Molecular Diagnostics Market Size Report

                       For More Report Details, Download Free Sample PDF

Global Molecular Diagnostics Market By Drivers & Restraints

Growing Elderly Population to fuel the target market growth

The increasing elderly population across the population worldwide is one of the key factors leading to the growth of the target market. The geriatric population is more prone to suffer from various diseases due to multi-morbidity, low immunity and aging related psychological changes. Thereby, the chance of developing various diseases, including diabetes, cancer, obesity, and neurological and cardiovascular issues, is rising as the geriatric population is rising, which in turn is boosting the growth of the Molecular Diagnostics Market.

For instance, in 2020, according to the UN report, it was reported that there were around 727 million people aged 65 years and above across the worldwide. Furthermore, the number of people aged 80 years and above are expected to double by 2050.

High Usage of PCR (Polymerase Chain Reaction) to boost the target market growth

The increased usage of PCR (Polymerase Chain Reaction) in various healthcare bodies, research institutes and hospitals is another key factor boosting the growth of the target market. PCR has a variety of applications in healthcare like genotyping, cloning, sequencing, microarrays and paternity testing, and has numerous advantages encouraging the healthcare industry to use it for various critical healthcare procedures, eventually propelling the growth of the Molecular Diagnostics Market.

For instance, in 2022, Seegene launched one of its successful products, “Allpex SARS-CoV-2 Fast PCR Assay. This test has a turnaround time for 60 minutes and hence is the perfect choice for mass testing.

Furthermore, the Covid 19 pandemic brought up a greater surge in the usage of PCR techniques in the healthcare industry recently.

Restrains:

The increasing regulatory approvals in this domain is the key factor restraining the growth of the Molecular Diagnostics Market. Many times, inaccurate results might be obtained due to a flaw in the diagnostic kits or a test being carried out by an unskilled person. As a result, the approval procedures are subjected to stringent control.

For instance, in October 2021, the testing for Covid-19 at a private laboratory in Wolverhampton had been suspended after an investigation by the UK Health Security Agency into media reports of an upsurge in the number of people receiving negative PCR test results after they had positive test results for Covid-19 on a lateral flow device.

Global Molecular Diagnostics Market By Segmentations & Regional Insights

Molecular Diagnostics Market is segmented based on Product, Technology, Application, End-User, and Region.

Product Insight

On the basis of Product, Molecular Diagnostics Market is segmented into Instruments, Reagents, and Other Products. The Reagents product segment is expected to dominate the growth of the target market due to the recurring cost associated with the frequent requirement of reagents. Furthermore, continuous technological advancements in this domain also have been leading to the development of new and improved reagents and kits.

Technology Insights

On the basis of Technology, Molecular Diagnostics Market is segmented into In Situ Hybridization, Chips and Microarrays, Mass Spectrometry (MS), Sequencing, PCR, and Other Technologies. The PCR (Polymerase Chain Reaction) Technology segment is expected to dominate the growth of the target market owing to its increased use in the detection of COVID-19 and various other infectious diseases.

Application Insights

On the basis of Service, Molecular Diagnostics Market is segmented into Infectious Disease, Oncology, Pharmacogenomics, Microbiology, Genetic Disease Screening, Human Leukocyte Antigen Typing, and Blood Screening. The Oncology Application segment is expected to dominate the growth of the target market owing to the rising prevalence of cancer diseases worldwide.

End-Users Insights

On the basis of End-Users, Molecular Diagnostics Market is segmented into Hospitals, Laboratories, and Other End Users. The Laboratories End-User segment is expected to dominate the growth of the target market as most of the procedures in this domain are carried out in laboratories under an appropriate environment and observance.

Regional Insights:

On the basis of Region, the Molecular Diagnostics Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the Molecular Diagnostics Market in the near future, owing to their advancements in technology, growing prevalence of infectious diseases as well as cancer diseases, improved healthcare facilities as well as increased research and development programs. 

Attribute

Details

Base year for estimation

2023

Forecast period

2024 – 2034

Market representation

Revenue in USD Billion & CAGR from 2024 to 2034

Market Segmentation

By Product - Instruments, Reagents, and Other Products.

By Technology - In Situ Hybridization, Chips and Microarrays, Mass Spectrometry (MS), Sequencing, PCR, and Other Technologies.  

By Application - Infectious Disease, Oncology, Pharmacogenomics, Microbiology, Genetic Disease Screening, Human Leukocyte Antigen Typing, and Blood Screening. 

By End-Users - Hospitals, Laboratories, and Other End Users. 

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Molecular Diagnostics Market report based on Product, Technology, Application, End-Users and Region:

Molecular Diagnostics Market, By Product:

  • Instruments
  • Reagents
  • Other Products

Molecular Diagnostics Market, By Technology:

  • In Situ Hybridization
  • Chips and Microarrays
  • Mass Spectrometry (MS)
  • Sequencing
  • PCR
  • Other Technologies

Molecular Diagnostics Market, By Application:

  • Infectious Disease
  • Oncology
  • Pharmacogenomics
  • Microbiology
  • Genetic Disease Screening
  • Human Leukocyte Antigen Typing
  • Blood Screening

Molecular Diagnostics Market, By End-Users:

  • Hospitals
  • Laboratories
  • Other End Users

Molecular Diagnostics Market, By Region:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East & Africa

Global Molecular Diagnostics Market By Competitive Landscape & Key Players

The key players operating the Molecular Diagnostics Market includes, F. Hoffmann-la Roche Ltd., Illumina Inc., Hologic Corporation, Agilent Technologies / Dako, Qiagen N.V., Myriad Genetics, BD (Becton, Dickinson and Company), Abbott Laboratories, Danaher Corporation (Cepheid Inc.), and Genomic Health Inc. 

Global Molecular Diagnostics Market By Recent News

Recent Development:

  • In May 2023, Hologic declared that the US FDA (Food and Drug Administration) had approved the "Panther Fusion SARS-CoV-2/Flu A/B/RSV test". The assay aids in the identification and distinction of four extremely frequent respiratory viruses, including influenza A, influenza B (SARS-CoV-2), and respiratory syncytial virus, which may display similar clinical signs.
  • In April 2023, Oxford Nanopore Technologies plc., and bioMérieux SA partnered up to introduce the latter's molecular sensing technology based on nanopores to the field of infectious illnesses. This sequencing technique tracks variations in electrical current as nucleic acids move through protein nanopores, decoding the signal to produce a particular RNA or DNA sequence.
  • In April 2023, QIAGEN said that their "QIAstat-Dx syndromic testing option" for use with a SARS-CoV-2 Respiratory Panel would soon be accessible in Japan. This would be the business' most recent foray into the more than 100 markets across the world at the moment.
  • In December 2021, Roche announced the completion of the acquisition with TIB Molbiol Group. TIB Molbiol Group has about 45 CE-IVD-approved assays for the diagnosis of infectious illnesses, inherited genetic disorders, transplant medicine, and haematology testing.
  • In July 2020, Roche Diagnostics India, announced the launch of the Cobas 8800 and the Cobas 6800 at the National Institute of Cholera and Enteric Diseases in Kolkata, which would help with SARS CoV-2 diagnostic testing. The Roche Cobas 6800/8800 systems can deliver fast test results in around three and a half hours and allow greater operational efficacy and flexibility.

Global Molecular Diagnostics Market By Company Profile

  • F. Hoffmann-la Roche Ltd.*
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Illumina Inc.
  • Hologic Corporation
  • Agilent Technologies / Dako
  • Qiagen N.V.
  • Myriad Genetics
  • BD (Becton, Dickinson and Company)
  • Abbott Laboratories
  • Danaher Corporation (Cepheid Inc.)
  • Genomic Health Inc.

“*” marked represents similar segmentation in other categories in the respective section

FAQs

Molecular diagnostics market is segmented on the basis of product type, application, end user, and region.

Increasing number of commercially available assays for screening of Hospital Acquired Infections (HAIs) is major factor driving growth of the molecular diagnostics market

The North America dominates the cell culture market owing to increasing presence of biopharmaceutical industries with increasing demand of precision medicine.

Key players operating in the molecular diagnostics market include Hologic,Inc., Grifols, S.A., Abbott Laboratories, Qiagen N.V., F. Hoffmann-La Roche Ltd., Siemens Healthineers, Becton, Dickinson and Company, and Beckman Coulter, Inc.

High cost of molecular diagnostics procedures, requirement of expensive laboratory equipments, and skilled professionals to operate them is some of the factors restraining growth of the market.

Molecular Diagnostics Market is driven by factors like growing elderly population and high usage of PCR (Polymerase Chain Reaction).

By Region, the Molecular Diagnostics Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period.

Molecular Diagnostics Market was valued at US$ 18.4 Billion in 2024 and is projected to grow at a CAGR of 11.50% to reach US$ 54.9 Billion by 2034.